Aspect Biosystems
Vancouver, Canada
Verified supplier · Last verified 3 Sep 2026
Aspect Biosystems is a Canadian biotechnology company founded in 2013 that develops bioprinted tissue therapeutics using proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. The company creates implantable allogeneic tissues designed to replace, repair, or supplement biological functions for metabolic and endocrine diseases. With over 100 employees and US$350M+ in capital raised, Aspect partners with leading pharmaceutical and biotechnology companies like Novo Nordisk to advance regenerative medicine.
What makes them different
Aspect Biosystems pioneered a full-stack tissue therapeutic platform integrating proprietary AI-powered bioprinting systems, microfluidic printheads, lab automation, software, and machine learning. The company is uniquely positioned as a biotech developer (not a 3D printing service provider) with expertise in advancing complex cell therapy and combination products through clinical development, led by executives with experience at Vertex Pharmaceuticals, ViaCyte, and BlueRock Therapeutics.
Industries served
- Regenerative Medicine
- Cell Therapy
- Metabolic Diseases
- Endocrine Diseases
- Pharmaceutical Development
Capacity
Over 100 employees; US$350M+ capital raised; developing clinical-stage bioprinted tissue therapeutics with partnerships including Novo Nordisk
Related Categories
Compare prices from verified suppliers or browse all suppliers.